Mustang Bio Announces Updated Results from Waldenstrom Macroglobulinemia Cohort of Ongoing Phase 1/2…
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed; one patient remains in complete remission at 22 months All patients were refractory to BTK…